AHCCCS Pharmacy and Therapeutics Committee Meeting Highlights
The AHCCCS Pharmacy and Therapeutics Committee meeting on October 19, 2016, covered various topics including antibiotic updates, new product reviews, and guidelines for cystic fibrosis treatments. Sarah Martinez, Pharm.D., provided insights on inhaled antibiotics and cytokine and CAM antagonists. The meeting minutes review emphasized the importance of comprehensive quality healthcare in Arizona.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
AHCCCS Pharmacy and Therapeutics Committee October 19, 2016
August 16, 2016 Meeting Minutes Review and Vote Reaching across Arizona to provide comprehensive quality health care for those in need 2
Magellan Class Reviews Classes o Antibiotics, Inhaled o Cytokine and CAM Antagonists o Epinephrine, Self-injected o Growth Hormone o Analgesics, Long-Acting Opioid o Makena (hydroxyprogesterone) Single Product Review New Products (to Magellan PDL classes) o Bevespi Aerosphere Reaching across Arizona to provide comprehensive quality health care for those in need 3
Antibiotics, Inhaled Sarah Martinez, Pharm D Provider Synergies Reaching across Arizona to provide comprehensive quality health care for those in need 4
Antibiotics, Inhaled Product Update: Kitabis Pak is now available as a generic Guideline Update: The Cystic Fibrosis Foundation guidelines for cystic fibrosis includes both nebulized tobramycin and aztreonam (Cayston) as recommended prophylaxis for Pseudomonas aeruginosa. Reaching across Arizona to provide comprehensive quality health care for those in need 5
Antibiotics, Inhaled The Cystic Fibrosis Foundation also recommends: The alternate-month administration of both tobramycin and aztreonam in patients persistently infected with P. aeruginosa, although with a grade B recommendation (high certainty that net benefit is moderate or moderate certainty that net benefit is substantial. Reaching across Arizona to provide comprehensive quality health care for those in need 6
Antibiotics, Inhaled Preferred Products: Kitabis Pak Bethkis Reaching across Arizona to provide comprehensive quality health care for those in need 7
Cytokine and CAM Antagonists Sarah Martinez, Pharm D Provider Synergies Reaching across Arizona to provide comprehensive quality health care for those in need 8
Cytokine and CAM Antagonists New Products/Product Updates: Taltz (ixekizumab) is indicated for the treatment of moderate to severe plaque psoriasis (reviewed in August) Cosentyx is now indicated for the treatment of psoriatic arthritis and ankylosing spondylitis in adults (previously indicated only for plaque psoriasis) Humira is now indicated for the treatment of non- infectious uveitis in adults Reaching across Arizona to provide comprehensive quality health care for those in need 9
Cytokine and CAM Antagonists New Products/Product Updates: Xeljanz XR (tofacitinib) is now available as a once daily administration option (11 mg tablets). Label information is similar for that for Xeljanz. o Caution should be used in patients with pre- existing gastrointestinal narrowing due to rare reports of obstructive symptoms in this population. o Should not be used when dose modifications are required Reaching across Arizona to provide comprehensive quality health care for those in need 10
Cytokine and CAM Antagonists Recent Studies: The CLEAR study was a manufacturer-funded 52-week comparison of Cosentyx and Stelara in patients with plaque psoriasis. Cosentyx treatment resulted in a statistically significant improvement in PASI 90 response compared to Stelara treatment at week 16. FIXTURE studied Cosentyx vs. placebo and Enbrel in plaque psoriasis. Cosentyx was found to be superior to Enbrel as a secondary endpoint in this manufacturer- sponsored, active-control study. Reaching across Arizona to provide comprehensive quality health care for those in need 11
Cytokine and CAM Antagonists Guideline Update: The American College of Rheumatology 2015 guidelines for treatment of rheumatoid arthritis recommend that non-TNF biologic is preferred in TNF inhibitor failure. o Xeljanz is generally recommended as an option following non-TNF biologic failure.
Cytokine and CAM Antagonists Guideline Update: The American College of Rheumatology released their first guideline on ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis. NSAIDs are recommended in patients with active AS. Those with active AS despite NSAID treatment should use a TNF blocker. No TNF blocker is listed as preferred over the others except in patients with concomitant irritable bowel disease or recurrent iritis, who should receive Remicade or Humira. Reaching across Arizona to provide comprehensive quality health care for those in need 13
Cytokine and CAM Antagonists Guideline Update: The American Gastroenterology Association (AGA) has created a clinical algorithm: o Recommends an anti-TNF agent with or without a thiopurine; or vedolizumab (Entyvio) with or without thiopurine or methotrexate, for maintenance therapy in high-risk outpatients following induction therapy. o If induction therapy is done with either an anti- TNF agent or vedolizumab, these agents should be continued.
Cytokine and CAM Antagonists AGA Guideline Update continued: In cases of loss of response to an anti-TNF agent, the anti-TNF dose should be optimized, and a switch within class, the addition of an immunomodulator, or a switch to vedolizumab may be considered. In cases of loss of response to vedolizumab, the dose should be optimized, and a switch to an anti- TNF agent may be considered. Infliximab may be used in inpatients who have failed IV steroids and for maintenance of remission.
Cytokine and CAM Antagonists Preferred Products: Enbrel Humira
Epinephrine, Self- injected Sarah Martinez, Pharm D Provider Synergies Reaching across Arizona to provide comprehensive quality health care for those in need 17
Epinephrine, Self-injected Class Overview No new clinical information to review Preferred Products Epinephrine 0.15 mg and 0.3 mg (generic Adrenaclick) Epipen Epipen Jr. Reaching across Arizona to provide comprehensive quality health care for those in need 18
Growth Hormone Sarah Martinez, Pharm D Provider Synergies Reaching across Arizona to provide comprehensive quality health care for those in need 19
Growth Hormone Product Updates Nutropin AQ pen cartridges have been discontinued by Genentech. The NuSpin device will remain available. Preferred Products Genotropin Nutropin Norditropin Reaching across Arizona to provide comprehensive quality health care for those in need 20
Analgesics, Long Acting Opioid Sarah Martinez, Pharm D Provider Synergies Reaching across Arizona to provide comprehensive quality health care for those in need 21
Analgesics, Long Acting Opioid Class Information Products include: Buprenorphine Fentanyl Hydromorphone Methadone Morphine Oxycodone Oxymorphone Tapentadol Tramadol across Arizona to provide comprehensive quality health care for those in need 22
Analgesics, Long Acting Opioid Abuse -Deterrent Products Morphine sulfate ER/naltrexone (Embeda) capsules; Hydrocodone ER (Hysingla ER) tablets; Oxycodone CR (OxyContin) tablets; Oxycodone ER (authorized generics for OxyContin) tablets: and Oxycodone ER (Xtampza ER) capsules. Reaching across Arizona to provide comprehensive quality health care for those in need 23
Analgesics, Long Acting Opioid Abuse -Deterrent Products continued Hydromorphone ER (Exalgo)* Oxymorphone ER (Opana ER)* Tapentadol ER (Nucynta ER)* Hydrocodone ER (Zohydro ER)* *Have abuse-deterrent properties but have not been approved by the FDA as abuse-deterrent Reaching across Arizona to provide comprehensive quality health care for those in need 24
Analgesics, Long Acting Opioid New Product: Belbuca (buprenorphine) Indicated for the management of severe pain that requires around-the-clock, long-term opioid treatment. Black box warning regarding addiction, abuse, and misuse; respiratory depression, accidental exposure; neonatal opioid withdrawal syndrome; and accidental exposure to children. Contraindicated in patients with significant respiratory depression, severe bronchial asthma, and suspected gastrointestinal obstruction. Reaching across Arizona to provide comprehensive quality health care for those in need 25
Analgesics, Long Acting Opioid New Product: Belbuca (buprenorphine) Warnings include use in elderly, cachectic, or debilitated patients or patients with chronic pulmonary disease; risk of prolonged QTc interval; severe hypotension; and risk of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness. Reaching across Arizona to provide comprehensive quality health care for those in need 26
Analgesics, Long Acting Opioid New Product: Belbuca (buprenorphine) Belbuca is a CYP3A4 substrate; it should be used with caution when initiating CYP3A4 inhibitors or discontinuing CYP3A4 inducers. Caution should be exercised when concomitantly giving CNS depressants, benzodiazepines, or mixed agonist/antagonist or partial agonist opioids. Common adverse effects include constipation, nausea, somnolence, vomiting, headache, and dizziness. Reaching across Arizona to provide comprehensive quality health care for those in need 27
Analgesics, Long Acting Opioid New Product: Belbuca (buprenorphine) There are no data available in pregnant women to inform a drug-associated risk, but limited published data on the use of buprenorphine in pregnant women have not shown increased risk of major malformations. Belbuca is applied once daily or every 12 hours, as tolerated. Lower doses are recommended in severe hepatic impairment or in the presence of oral mucositis. It is available in seven strengths ranging from 75 to 900 mcg buccal films. Reaching across Arizona to provide comprehensive quality health care for those in need 28
Analgesics, Long Acting Opioid New Product: Xtampza ER (oxycodone) Indicated for the management of severe pain that requires around-the-clock, long-term opioid treatment. Black box warning regarding addiction, abuse, and misuse; respiratory depression, accidental ingestion; neonatal opioid withdrawal syndrome; concomitant use with CYP3A4 inhibitors; and accidental exposure to children. Contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, and suspected gastrointestinal obstruction. Reaching across Arizona to provide comprehensive quality health care for those in need 29
Analgesics, Long Acting Opioid New Product: Xtampza ER (oxycodone) Other warnings include use in elderly, cachectic, or debilitated patients or patients with chronic pulmonary disease; adrenal insufficiency; severe hypotension; and risk of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness. Xtampza ER is a CYP3A4 substrate. It should also be used with caution when used concurrently with CNS depressants, serotonergic drugs, and mixed agonist/antagonist or partial agonist opioids. Reaching across Arizona to provide comprehensive quality health care for those in need 30
Analgesics, Long Acting Opioid New Product: Xtampza ER (oxycodone) Common adverse effects include nausea, headache, constipation, somnolence, and pruritus. There are no data available in pregnant women to inform a drug-associated risk, but prolonged use can lead to neonatal opioid withdrawal syndrome. Xtampza ER is given every 12 hours with food. The capsule contents can be sprinkled on food. Lower doses are recommended in severe hepatic impairment. Reaching across Arizona to provide comprehensive quality health care for those in need 31
Analgesics, Long Acting Opioid New Product: Xtampza ER (oxycodone) continued It is available in five strengths ranging from 9 to 36 mg extended release capsules. The abuse deterrent mechanism is the microsphere formulation (inactive ingredients) that makes the capsule contents difficult to manipulate for misuse and abuse. Reaching across Arizona to provide comprehensive quality health care for those in need 32
Analgesics, Long Acting Opioid Guideline/Regulatory Updates: Centers for Disease Control and Prevention (CDC) released guidelines for prescribing opioids for chronic pain outside of active cancer, palliative, and end-of-life care If opioids are deemed appropriate for a patient s chronic pain, they recommend initial treatment with immediate-release opioids Doses of 50 morphine milligram equivalents (MME)/day should prompt reassessment of the individual s benefits and risks and use of 90 MME/day should be avoided Reaching across Arizona to provide comprehensive quality health care for those in need 33
Analgesics, Long Acting Opioid Guideline/Regulatory Updates continued: A black boxed warning will be added to all opioid- and benzodiazepine-containing product labels stating that concomitant use of opioids and benzodiazepines has resulted in serious adverse effects, including respiratory depression and death. Reaching across Arizona to provide comprehensive quality health care for those in need 34
Makena (hydroxyprogesterone) Sarah Martinez, Pharm D Provider Synergies Reaching across Arizona to provide comprehensive quality health care for those in need 35
Makena (hydroxyprogesterone) Indication: To reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth Women who have had a previous preterm birth are at increased risk for premature birth. Preterm birth, defined as birth of an infant prior to 37 week of gestation, affects nearly 1 of every 9 infants born in the U.S. each year (CDC July 2016) There is a higher risk of serious disability or death the earlier the baby is born. Preterm-related causes of death accounted for 35% in 2008 of all infant deaths.
Makena (hydroxyprogesterone) Dosing: Administer 250 mg (1 mL) intramuscular (IM) every 7 days; Begin treatment between 16 weeks, 0 days and 20 weeks, 6 days of gestation; Continue administration once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first Available as multidose vial: 5 mL (250 mg/mL) and single-dose vial (preservative-free): 1 mL (250 mg/mL)
New Products (to Magellan PDL classes) Sarah Martinez, Pharm D Provider Synergies Reaching across Arizona to provide comprehensive quality health care for those in need 38
Bevespi Aerosphere (formoterol/glycopyrrolate) Indicated for the long-term maintenance treatment of airflow obstruction in COPD patients Black box warning regarding asthma-related death due to its LABA component as well as a notice that the product is not indicated for treatment of asthma Contraindication with use of LABA without long-term controller medication for asthma despite the lack of asthma indication
Bevespi Aerosphere (formoterol/glycopyrrolate) Other warnings include inappropriate use in acute symptom treatment, paradoxical bronchospasm, hypokalemia/hyperglycemia, worsening of urinary retention and/or narrow- angle glaucoma, and use in patients with cardiovascular disorders, convulsive disorders, thyrotoxicosis, diabetes, and ketoacidosis Use with caution when concurrently given with MAO inhibitors, tricyclic antidepressants, anticholinergics, xanthine derivatives, diuretics, or beta blockers
Bevespi Aerosphere (formoterol/glycopyrrolate) Common adverse effects include urinary tract infection and cough It is in pregnancy category C Given as two inhalations twice daily It is available as a 4.8 mcg/9 mcg metered dose inhaler Reaching across Arizona to provide comprehensive quality health care for those in need 41
Oral Oncology Drugs Subcommittee Follow-up Suzi Berman Reaching across Arizona to provide comprehensive quality health care for those in need 42
HIV Subcommittee Follow-up Suzi Berman Reaching across Arizona to provide comprehensive quality health care for those in need 43
NEW DRUGS Xiidra Lifitegrast Ophthalmic Solutions Zinbryta - Daclizumab Ocaliva Obeticholic Acid Briviact - Brivaracetam Reaching across Arizona to provide comprehensive quality health care for those in need 44
Xiidra Lifitegrast Ophthalmic Solutions Indicated for dry eye disease Dosage: 1 drop in eye(s) every 12 hours Black Box Warning - None Clinical Trials o Double-blinded Study o 1181 patients 1067 received Xiidra placed into 4 groupings. o Majority of participants were female average age of 59 years. Reaching across Arizona to provide comprehensive quality health care for those in need 45
Xiidra Lifitegrast Ophthalmic Solutions Clinical Trials Continued: Results were based on the: Eye Dryness Score (EDS) A score of 100 is maximal discomfort Baseline EDS scores were: 50 for Study Groups 1 & 2 70 for Study Groups 3 & 4 Over the 12 week trials, the average reductions were: 14.5 points for Study Groups 1 & 2 36.5 points for Study Groups 3 & 4 Reaching across Arizona to provide comprehensive quality health care for those in need 46
Xiidra Lifitegrast Ophthalmic Solutions Adverse reactions o Irritation, dysgeusia (foul, salty, rancid, or metallic taste sensation in the mouth) and reduced visual acuity in 5-25% of the patients o Blurred vision, conjunctival redness, eye irritation, headache, increased tearing, eye discharge, eye discomfort, eye pruritus and sinusitis in 1-5% of the patients. Reaching across Arizona to provide comprehensive quality health care for those in need 47
Xiidra Lifitegrast Ophthalmic Solutions Recommendation: o Xiidra is the only FDA approved drug to treat the signs and symptoms of dry eye disease. The disease can be mild to severe and other products listed on the AHCCCS Drug List have been tried with success. o AHCCCS does not recommend adding Xiidra to the AHCCCS Drug List at this time. o Xiidra is available with prior authorization. Reaching across Arizona to provide comprehensive quality health care for those in need 48
Zinbryta - Daclizumab Indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Due to its safety profile, Zinbryta should generally be reserved for patients who have had an inadequate response to two or more MS drugs. Reaching across Arizona to provide comprehensive quality health care for those in need 49
Zinbryta - Daclizumab Dosage: 150mg subcutaneously once monthly Black Box Warnings: o Zinbryta can cause severe liver injury including life-threatening events including liver failure and autoimmune hepatitis. o Contraindicated for use in patients with pre- existing hepatic disease or impairment. o Other Immune-Mediated Disorders Reaching across Arizona to provide comprehensive quality health care for those in need 50
